Quantum Biopharma Ltd. (NASDAQ:QNTM) Sees Significant Growth in Short Interest

Quantum Biopharma Ltd. (NASDAQ:QNTM) saw a large increase in short interest in the month of May. As of May 29th, there was short interest totaling 411,604 shares, an increase of 85.7% from the May 14th total of 221,665 shares. Approximately 11.8% of the shares of the company are short sold. Based on an average daily trading volume, of 620,229 shares, the short-interest ratio is currently 0.7 days.

Wall Street Analyst Weigh In

Several research analysts recently commented on QNTM shares. Wall Street Zen downgraded shares of Quantum Biopharma from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Weiss Ratings downgraded shares of Quantum Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, May 28th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, Quantum Biopharma presently has an average rating of “Sell”.

Quantum Biopharma Price Performance

NASDAQ:QNTM traded down $0.06 during trading hours on Tuesday, hitting $3.64. The stock had a trading volume of 94,988 shares, compared to its average volume of 342,641. The company has a 50 day simple moving average of $4.98 and a two-hundred day simple moving average of $5.58. Quantum Biopharma has a one year low of $2.07 and a one year high of $38.25. The firm has a market capitalization of $13.90 million, a price-to-earnings ratio of -0.44 and a beta of 0.35.

Quantum Biopharma (NASDAQ:QNTM) last announced its quarterly earnings results on Thursday, March 26th. The company reported ($0.71) EPS for the quarter, missing the consensus estimate of ($0.22) by ($0.49).

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of QNTM. Jane Street Group LLC bought a new stake in shares of Quantum Biopharma during the 4th quarter worth $80,000. Virtu Financial LLC bought a new stake in shares of Quantum Biopharma during the 4th quarter worth $76,000. Finally, Platform Technology Partners bought a new stake in shares of Quantum Biopharma during the 1st quarter worth $199,000. 1.24% of the stock is owned by institutional investors.

About Quantum Biopharma

Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company’s three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property.